Qualification of novel methodologies for medicinal product development: guidance to applicants

Human medicines European public assessment report (EPAR): Tysabri, natalizumab, Date of authorisation: 27/06/2006, Revision: 53, Status: Authorised

Agenda of the PRAC meeting 6-9 July 2026

Agenda of the HMPC meeting 6-8 July 2026

List of signals discussed at PRAC since September 2012

Start of procedure: Type II Variation - Extension of indication under evaluation by the CHMP (22 May 2026 - 25 June 2026)

Start of procedure: Extension of marketing authorisation (22 May 2026 - 25 June 2026)

Human medicines European public assessment report (EPAR): Alprolix, eftrenonacog alfa, Date of authorisation: 12/05/2016, Revision: 12, Status: Authorised

Seventeenth Industry Standing Group (ISG) meeting, Online, from 29 June 2026, 09:30 (CEST) to 29 June 2026, 13:10 (CEST)

17th Industry Standing Group (ISG) meeting, Online, from 29 June 2026, 09:30 (CEST) to 29 June 2026, 13:10 (CEST)